摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(((1-fluoronaphthalen-2-yl)oxy)methyl)oxirane | 1055052-15-7

中文名称
——
中文别名
——
英文名称
2-(((1-fluoronaphthalen-2-yl)oxy)methyl)oxirane
英文别名
1-fluoro-2-(oxiran-2-ylmethoxy)naphthalene;2-[(1-Fluoronaphthalen-2-yl)oxymethyl]oxirane
2-(((1-fluoronaphthalen-2-yl)oxy)methyl)oxirane化学式
CAS
1055052-15-7
化学式
C13H11FO2
mdl
——
分子量
218.228
InChiKey
CKLYNKVPJLVQDN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    21.8
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    1-氟-2-萘酚环氧溴丙烷caesium carbonate 作用下, 以 二氯甲烷 为溶剂, 反应 24.0h, 以43%的产率得到2-(((1-fluoronaphthalen-2-yl)oxy)methyl)oxirane
    参考文献:
    名称:
    C(sp3)-亲电子试剂对卤萘酚的无过渡金属脱芳构化
    摘要:
    描述了卤代萘酚与苄基/烯丙基溴的第一次分子间亲电脱芳构化。卤代萘酚作为碳亲核试剂在脱芳构化中形成具有优异化学选择性的三维环状烯酮,其中以碳酸铯为碱可以很好地抑制酚羟基的醚化。从各种取代的苄基/烯丙基溴和卤代萘酚直接制备出范围广泛的环状烯酮。机理研究表明直接的 S N 2 反应途径。
    DOI:
    10.1016/j.cclet.2021.10.037
点击查看最新优质反应信息

文献信息

  • Substituted heterocyclic compounds
    申请人:——
    公开号:US20030176447A1
    公开(公告)日:2003-09-18
    Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes, and for increasing HDL plasma levels in mammals.
    揭示了一种新颖的杂环衍生物,用于治疗各种疾病状态,特别是心血管疾病,如心房和心室心律失常、间歇性跛行、普林兹梅塔(变异)心绞痛、稳定和不稳定心绞痛、运动诱发性心绞痛、充血性心力衰竭和心肌梗死。这些化合物还可用于治疗糖尿病,并可增加哺乳动物的高密度脂蛋白血浆水平。
  • [EN] SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISEASES<br/>[FR] COMPOSES HETEROCYCLIQUES SUBSTITUES UTILES POUR LE TRAITEMENT DE MALADIES CARDIO-VASCULAIRES
    申请人:CV THERAPEUTICS INC
    公开号:WO2004069818A1
    公开(公告)日:2004-08-19
    wherein: a.o. T is oxygen, sulfur, or NR11 , in which R11 is hydrogen or lower alkyl; V is -N<, -CH<, or -NH-CH<; X1 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; X2 is optionally substituted aryl or optionally substituted heteroaryl; Y is optionally substituted dihydroheteroarcyl; and Z1 and Z2 are independently optionally substituted alkylene of 1-4 carbon atoms, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal’s (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.
    其中:a.o. T是氧、硫或NR11,其中R11是氢或较低的烷基;V是-N<,-CH<或-NH-CH<;X1是氢,可选择取代的较低烷基,可选择取代的环烷基,可选择取代的芳基或可选择取代的杂芳基;X2是可选择取代的芳基或可选择取代的杂芳基;Y是可选择取代的二氢杂芳基;Z1和Z2分别是1-4个碳原子的可选择取代的烷基,用于治疗各种疾病状态,特别是心血管疾病,如心房和心室心律失常、间歇性跛行、普林兹梅塔(变异)心绞痛、稳定和不稳定心绞痛、运动诱发性心绞痛、充血性心脏病和心肌梗死。这些化合物还可用于治疗糖尿病。
  • [EN] SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS<br/>[FR] COMPOSES DE PIPERAZINE SUBSTITUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE L'OXYDATION D'ACIDES GRAS
    申请人:CV THERAPEUTICS INC
    公开号:WO2003008411A1
    公开(公告)日:2003-01-30
    Disclosed are novel heterocyclic derivatives of the formula (I), wherein amongst others R?1, R2, R3, R4, R5, R6, R7, and R8¿ are hydrogen; T is oxygen, sulfur, or NR11, in which R11 is hydrogen or lower alkyl; V is N<, -CH<, or N-CH<; X1 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; X2 is optionally substituted aryl or optionally substituted heteroaryl; Y is optionally substituted monocyclic heteroarylenyl; and Z?1 and Z2¿ are independently optionally substituted alkylene or 1-4 carbon atoms. The compounds are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes, and for increasing HDL plasma levels in mammals.
    本发明涉及一种新型杂环衍生物的公开式(I),其中,R1、R2、R3、R4、R5、R6、R7和R8中的一些是氢;T为氧、硫或NR11,其中R11为氢或低碳基;V为N<、-CH<或N-CH<;X1为氢、可选取代的低碳基、可选取代的环烷基、可选取代的芳基或可选取代的杂环芳基;X2为可选取代的芳基或可选取代的杂环芳基;Y为可选取代的单环杂芳基;Z1和Z2独立地为可选取代的烷基或1-4碳原子。该化合物可用于治疗各种疾病状态,特别是心血管疾病,如心房和心室心律失常、间歇性跛行、普林兹梅塔尔(变异型)心绞痛、稳定和不稳定性心绞痛、运动诱发性心绞痛、充血性心力衰竭和心肌梗死。该化合物还可用于治疗糖尿病,并可提高哺乳动物的高密度脂蛋白血浆水平。
  • SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS
    申请人:CV THERAPEUTICS, INC.
    公开号:EP1406898A1
    公开(公告)日:2004-04-14
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    申请人:CV Therapeutics Inc.
    公开号:EP1583760A2
    公开(公告)日:2005-10-12
查看更多